Ebsteins anomaly of the tricuspid valve Microchapters

Home

Patient Information

Overview

Historical Perpective

Classification

Pathophysiology

Causes

Differentiating Ebstein's Anomaly from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography

MRI

Other Imaging Findings

Other diagnostic studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Ebsteins anomaly of the tricuspid valve primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ebsteins anomaly of the tricuspid valve primary prevention

CDC on Ebsteins anomaly of the tricuspid valve primary prevention

Ebsteins anomaly of the tricuspid valve primary prevention in the news

Blogs on Ebsteins anomaly of the tricuspid valve primary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview[edit | edit source]

In so far as Lithium and benzodiazepines have been associated with an increased risk of Ebstein's anomaly, these drugs should be avoided if possible in the first trimester of pregnancy.

## Primary prevention[edit | edit source]

## ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT)[1][2][edit | edit source]

### Endocarditis Prophylaxis (DO NOT EDIT)[1][2][edit | edit source]

Class IIa

"1. Antibiotic prophylaxis before dental procedures that involve manipulation of gingival tissue or the periapical region of the teeth or perforation of the oral mucosa is reasonable in cyanotic patients with Ebstein’s anomaly and postoperative patients with a prosthetic cardiac valve. (Level of Evidence: C)"

## References[edit | edit source]

1. ↑ 1.0 1.1 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease)". Circulation. 118 (23): 2395–451. doi:10.1161/CIRCULATIONAHA.108.190811. PMID 18997168.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
2. ↑ 2.0 2.1 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS